Paediatric Clinical Neurology
Basic and Clinical Pharmacology, 11th Edition
The most trusted and up-to-date pharmacology text in medicine — completely redesigned to make the learning process even more interesting and efficient
A Doody’s Core Title ESSENTIAL PURCHASE for 2011!
5 Star Doody’s Review!
“This is the most widely used textbook for teaching pharmacology to health professionals. This 11th edition is far superior to any previous editions….The authors’ goals are to provide a complete, authoritative, current, and readable textbook of pharmacology for students in health sciences. Testimony to their success is the widespread use of this work as required textbook for pharmacology courses around the world. This book is used extensively by thousands of medical, pharmacy, podiatry, nursing, and other health professions students to study pharmacology. Likewise, it remains a valuable resource for residents and practicing physicians….I continue to use this book as a required resource for all courses that I teach to medical, nursing, and allied health students. It is authoritative, readable, and supported by numerous learning tools.”–Doody’s Review Service
Organized to reflect the syllabi in Pharmacology courses, Basic & Clinical Pharmacology covers all the important concepts students need to know about the science of pharmacology and its application to clinical practice. It is acknowledged worldwide as the field’s most current, authoritative, and comprehensive textbook. To be as clinically relevant as possible, the book features a strong focus on the choice and use of drugs in patients and the monitoring of their effects. Read More…
Latest News from Pharma Industry:
Low glycemic diet does not improve risk factors for cardiovascular disease and diabetes
Nutrition experts are continually debating the nutritional value of carbohydrate-containing foods and whether some are healthier than others. High carbohydrate foods are classified by how much they increase blood sugar; known as glycemic index. In new findings led by researchers at Brigham and Women's Hospital (BWH) in Boston and Johns Hopkins University (JHU) in Baltimore, researchers looked at
New targeted drugs could treat drug-resistant skin cancer
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports. Clinical trials to test the new drugs in patients should begin as early as 2015. Existing drugs target faulty versions of a protein called BRAF which drives about half of all melanomas, but while initially very effective, the cancers almost always become resistant to treatment within a year.
Injectable 3D vaccines could fight cancer and infectious diseases
One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. Now, researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard's School of Engineering and Applied Sciences (SEAS) show a non-surgical injection of programmable biomaterial that spontaneously assembles in vivo into a 3D structure could fight and even help prevent cancer and also infectious disease such as HIV.
Abbott completes acquisition of Veropharm
Abbott (NYSE: ABT) today announced that it has acquired control of Veropharm, a leading Russian pharmaceutical manufacturer. Abbott has had a presence in Russia for nearly 40 years and, in line with its long-term commitment to growing global healthcare markets and capabilities, the company is committed to providing a reliable supply of its healthcare products to Russian patients.
Can researchers develop 100 drugs in 10 years?
Develop 100 drugs in 10 years. That's the ambitious goal set by a group of scientists and engineers at the University of Utah, founders of Recursion Pharmaceuticals, a start-up company that is able to quickly and affordably identify unexpected ways a drug could be used by testing it on diseased cells.